drugset / Trial / NCT05648591
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
Timeline
- Start
- 2023-05-24
- Primary completion
- 2026-03-31
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iloperidone | Small molecule | — | Oral |